Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Wang, Xue; Sun, Yile; Xu, Yunhua; Wen, Danyi; An, Na; Leng, Xuejiao; Fu, Guolong; Lü, Shun; Chen, Zhiwei

doi:10.1002/cbin.11622

Cited by 7 publications

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, the study by Yang et al showed a significant benefit from the MiniPDX test than the control group in hepatocellular carcinoma (DFS: 25.8 months vs. 18.2 months, P=0.022) (35). Similar results were validated in ovarian cancer (36) and lung cancer (37). In our study, individual chemotherapy based on MiniPDX also showed superiority to prolong the OS and PFS of patients with GCLM, which could consider solid validation evidence for previous studies.…”

Section: Discussionsupporting

confidence: 86%

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

Zhang

Liang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundIt is estimated that 35% of gastric cancer patients appear with synchronous distant metastases—the vast majority of patients presenting with metastatic hepatic disease. How to choose the most appropriate drugs or regimens is crucial to improve the prognosis of patients. We conducted this retrospective cohort analysis to evaluate the efficacy of OncoVee™-MiniPDX-guided treatment for these patients.MethodsGastric cancer patients with liver metastases (GCLM) were enrolled. Patients were divided into MiniPDX and control group according to their wishes. In the observation group, the OncoVee™-MiniPDX model was conducted to screen the most sensitive drug or regimens to determine the clinical administration. Meanwhile, patients were treated with regular medications in the control group according to the guidelines without the MiniPDX model. The primary endpoint was overall survival (OS), and the secondary outcomes included objective response rate (ORR), disease control rate (DCR), and progression-free survival (PFS).ResultsA total of 68 patients with GCLM were included, with the observation and control groups of 21 and 47 patients, respectively. The baseline characteristics of patients were balanced between these two groups. MiniPDX drug sensitivity tests were associated with the increased use of targeted drugs when compared with the control group (33.3 vs. 0%, p=0.032). Median OS was estimated to be 9.4 (95% CI, 7.9–11.2) months and 7.9 (95% CI, 7.2–8.7) months in the observation and control group, respectively. Both univariate (control group vs. MiniPDX group: HR=2.586, 95% CI= 1.362–4.908, p=0.004) and multivariate regression analyses (Control group vs. MiniPDX group: adjusted HR (aHR)=4.288, 95% CI= 1.452–12.671, p=0.008) showed the superiority of the observation group on OS. Similarly, MiniPDX-based regiments significantly improve the PFS of these cases (median PFS 6.7 months vs. 4.2 months, aHR=2.773, 95% CI=1.532–3.983, p=0.029). ORR and DCR were also improved in MiniPDX group comparing with control group (ORR, 57.14 vs. 25.53%, p=0.029; DCR: 85.71 vs. 68.08%, p=0.035).ConclusionOncoVee™-MiniPDX model, which was used to select drugs to guide antitumor treatment, was promising to prolong survival and improve the response rate of patients with GCLM. Further well-designed studies are needed to confirm the clinical benefits of MiniPDX.

show abstract

Section: Discussionsupporting

confidence: 86%

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

Zhang

Liang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…14 Individualized chemotherapy regimens for platinumresistant ovarian cancer cases identified through the circulating tumor DNA assay and the MiniPDX drug screening system showed an overall clinical benefit of 75.0%. 15 Similarly, individualized chemotherapy regimens screened by MiniPDX have been applied for progressive non-small cell lung cancer 16 and metastatic rectal cancer. 17 Specifically, a recent study using individualized chemotherapy regimens screened by MiniPDX reported that the MiniPDX group had a significantly higher tumor-free survival rate and longer OS than the control group (receiving treatment with sorafenib) (Yang et al, 2021).…”

Section: Discussionmentioning

confidence: 99%

Individualized chemotherapy and efficacy analysis of hepatoblastoma in children

Hu,

Zhang,

Zhang

et al. 2023

Pediatric Blood & Cancer

View full text Add to dashboard Cite

PurposeWe aimed to assess the clinical utility of the mini patient‐derived xenograft (MiniPDX) model in screening individualized chemotherapy regimens for pediatric hepatoblastoma.Materials and methodsWe included 31 children with hepatoblastoma who had unsatisfactory decreases in alpha‐fetoprotein levels during neoadjuvant chemotherapy or poor clinical control of recurrence with or without metastasis. We established a MiniPDX model using surgically resected tumor tissue specimens. The sensitivities of five chemotherapeutic regimens were tested to determine the one with the lowest tumor proliferation rate, which was then set as the experimental group. We compared the clinical characteristics and efficacy with those of conventional chemotherapy regimens.ResultsThe median follow‐up period for the experimental group was 27 months, with a complete remission (CR) rate of 80.64%. Among stage IV cases, there was a significant between‐group difference in CR rate (experimental [73.68%] vs. control [37.5%]) and 3‐year event‐free survival rate (79.3% vs. 26.7%). The most effective individualized chemotherapy regimens were ifosfamide + pirarubicin + etoposide + carboplatin (54.84%), followed by pirubicin + cyclophosphamide + cisplatin (16.13%), ifosfamide + carboplatin + etoposide (12.90%), cisplatin + 5‐fluorouracil + vincristine + adriamycin (12.90%), and vincristine + irinotecan + cyclophosphamide + cisplatin (3.23%).ConclusionUsing the MiniPDX model to screen individualized chemotherapy regimens for pediatric hepatoblastoma can significantly improve the CR rate.

show abstract

“…In a study on patients with platinum-resistant ovarian cancer, the clinical treatment response rate guided by MiniPDX drug sensitivity detection can be as high as 75% [ 99 ]. To treat patients with non-small cell lung cancer, Chen et al confirmed that the MiniPDX-guided treatment group showed a better OS and PFS than the conventional chemotherapy group [ 100 ]. Li and colleagues verified the drug response predicted by WES, proteomics, and phosphorproteomics on the MiniPDX model and established an entire workflow from the generation of large omics datasets to in vivo drug testing models of colorectal cancer [ 101 ].…”

Section: Minipdxmentioning

confidence: 99%

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

Long

Xie

Shen

et al. 2022

Cells

Self Cite

View full text Add to dashboard Cite

As one of the leading causes of death from disease, cancer continues to pose a serious threat to human health globally. Despite the development of novel therapeutic regimens and drugs, the long-term survival of cancer patients is still very low, especially for those whose diagnosis is not caught early enough. Meanwhile, our understanding of tumorigenesis is still limited. Suitable research models are essential tools for exploring cancer mechanisms and treatments. Herein we review and compare several widely used in vitro and in vivo murine cancer models, including syngeneic tumor models, genetically engineered mouse models (GEMM), cell line-derived xenografts (CDX), patient-derived xenografts (PDX), conditionally reprogrammed (CR) cells, organoids, and MiniPDX. We will summarize the methodology and feasibility of various models in terms of their advantages and limitations in the application prospects for drug discovery and development and precision medicine.

show abstract

Mini‐patient‐derived xenograft assay based on microfluidic technology promises to be an effective tool for screening individualized chemotherapy regimens for advanced non‐small cell lung cancer

Cited by 7 publications

References 24 publications

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

OncoVee™-MiniPDX-Guided Anticancer Treatment for Gastric Cancer Patients With Synchronous Liver Metastases: A Retrospective Cohort Analysis

Individualized chemotherapy and efficacy analysis of hepatoblastoma in children

Translation Potential and Challenges of In Vitro and Murine Models in Cancer Clinic

Contact Info

Product

Resources

About